ViroMed Co., Ltd. (VM BioPharma in the US) is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA and protein-based therapeutics for various life-threatening diseases, and herbal-based medicines and nutraceuticals. ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials in the US, Korea, and China. The company has established several key partnerships with global firms including Johnson & Johnson (Biologics Delivery Systems Group of Cordis Corp., USA), SBI Biotech (Japan), and Green Cross (Korea). The company also conducts preclinical developmental studies in the aspects of toxicology, efficacy a
| Attributes | Values |
|---|
| rdfs:label
| |
| rdfs:comment
| - ViroMed Co., Ltd. (VM BioPharma in the US) is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA and protein-based therapeutics for various life-threatening diseases, and herbal-based medicines and nutraceuticals. ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials in the US, Korea, and China. The company has established several key partnerships with global firms including Johnson & Johnson (Biologics Delivery Systems Group of Cordis Corp., USA), SBI Biotech (Japan), and Green Cross (Korea). The company also conducts preclinical developmental studies in the aspects of toxicology, efficacy a
|
| sameAs
| |
| dbkwik:speedydelet...iPageUsesTemplate
| |
| concern
| |
| Timestamp
| - 20120708075357(xsd:double)
|
| abstract
| - ViroMed Co., Ltd. (VM BioPharma in the US) is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA and protein-based therapeutics for various life-threatening diseases, and herbal-based medicines and nutraceuticals. ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials in the US, Korea, and China. The company has established several key partnerships with global firms including Johnson & Johnson (Biologics Delivery Systems Group of Cordis Corp., USA), SBI Biotech (Japan), and Green Cross (Korea). The company also conducts preclinical developmental studies in the aspects of toxicology, efficacy and pharmacokinetics. Phase I and II clinical studies are also carried out.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)